Differential Immunogenicity of A Recombinant Hepatitis B Vaccine in Iranian Neonates: Influence of Ethnicity and Environmental Factors

Authors

  • Abdollah Jafarzadeh Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran | Department of Immunology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan
  • Babak Faraj Mazaheri Health Research Center of Urmia, Institute of Public Health Research, Tehran University of Medical Sciences, Tehran, Iran
  • Fazel Shokri Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran
  • Jalal Khoshnoodi Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran
  • Saleh Mohaghegh Hazrati Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran | Health Research Center of Urmia, Institute of Public Health Research, Tehran University of Medical Sciences, Tehran, Iran
  • Shayesteh Ghorbani Kerman Health Center, Kerman University of Medical Sciences, Kerman
Abstract:

Objective: To compare immunogenicity of a recombinant hepatitis B (HB) vaccine in two groups of neonates born in two cities of Iran with different geographic and ethnic backgrounds.   Materials and Methods: Ten micrograms of a recombinant HB vaccine was administered under field condition to Iranian healthy neonates at 0, 1.5 and 9 months intervals. The subjects consisted of two groups of 290 and 231 neonates selected from two cities located at north-west (Urmia) and south-east (Kerman) of Iran, respectively. The level of anti-HBs antibody was quantitated in serum 2-4 weeks after administration of the last vaccine dose, by sandwich ELISA.   Results: A higher seroprotection rate (anti-HBs> 10 IU/L) (98.3% vs. 96.1%) and significantly increased serum anti- HBs antibody titer (11869 vs. 6104 IU/L) (P

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

differential immunogenicity of a recombinant hepatitis b vaccine in iranian neonates: influence of ethnicity and environmental factors

objective: to compare immunogenicity of a recombinant hepatitis b (hb) vaccine in two groups of neonates born in two cities of iran with different geographic and ethnic backgrounds.   materials and methods: ten micrograms of a recombinant hb vaccine was administered under field condition to iranian healthy neonates at 0, 1.5 and 9 months intervals. the subjects consisted of two groups of 290 an...

full text

Unresponsiveness to Recombinant Hepatitis B Vaccine in Healthy Iranian Neonates: Association with HLA Antigens

Background: Hepatitis B is an important infectious disease.  Since several years ago, mass vaccination against this viral infection has become as part of routine vaccination schedule of Iran.  However, some healthy neonates, children and adults fail to generate a protective antibody response after vaccination.Objectives: To investigate distribution of HLA class-I and class-II antigens in health...

full text

Safety and Immunogenicity of Hepatitis B Vaccine: a Study on Iranian Navy Personnel

Objective: Preventing communicable diseases in the armed forces (AF) of a country is considered as a national interest and has a great importance. There are limited data on the efficacy of vaccination of the navy personnel. This study was designed to evaluate both the safety and the immunogenicity of a recombinant hepatitis B (HB) vaccine made by Pasteur Institute of Iran (IPI-rHB), in this tar...

full text

Evaluation of Thimerosal Removal on Immunogenicity of Aluminum Salts Adjuvanted Recombinant Hepatitis B Vaccine

     Thimerosal, which is approximately 50% mercury by weight is a preservative widely used in vaccines since the 1930’s. It meets the requirements for a preservative as set forth by Pharmacopeia challenge test and has been shown to be effective against a broad spectrum of pathogens. In July 1999, the Public Health Service agencies and vaccine manufacturers agreed that thimerosal should be redu...

full text

Downregulation of IL-12 Production in Healthy Non-Responder Neonates to Recombinant Hepatitis B Vaccine

A proportion of healthy neonates and adults fail to develop a protective antibody response to recombinant hepatitis B (HB) vaccine. Unresponsiveness to vaccination could be attributed to defect in a number of immunological regulatory mechanisms. In this study, IL-12 was quantitated in culture supernatant following in vitro stimulation of peripheral blood mononuclear cells isolated from a group ...

full text

Evaluation of Thimerosal Removal on Immunogenicity of Aluminum Salts Adjuvanted Recombinant Hepatitis B Vaccine

     Thimerosal, which is approximately 50% mercury by weight is a preservative widely used in vaccines since the 1930’s. It meets the requirements for a preservative as set forth by Pharmacopeia challenge test and has been shown to be effective against a broad spectrum of pathogens. In July 1999, the Public Health Service agencies and vaccine manufacturers agreed that thimerosal should be redu...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 1  issue 2

pages  98- 104

publication date 2004-09-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023